Yadav Budhi Singh, Loganathan Sofia, Sharma Suresh C, Singh Rajinder, Dahiya Divya
Department of Radiation Oncology, Regional Cancer Centre, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
Department of Radiation Oncology, Government Medical College, Trichy, Tamilnadu, India.
Adv Radiat Oncol. 2019 Sep 27;5(2):171-179. doi: 10.1016/j.adro.2019.09.005. eCollection 2020 Mar-Apr.
To compare rates of acute and late skin toxicities and cosmetic outcomes after accelerated partial breast irradiation (APBI) or whole breast irradiation (WBI) using 3-dimensional conformal external beam radiation therapy in women with breast cancer after breast conservation surgery (BCS).
Women >35 years of age with invasive or noninvasive breast cancer ≤4 cm treated by BCS were randomized to 3D-CRT APBI (34 Gy/10 fractions/5 days) or WBI (40 Gy/16 fractions/3 weeks ± boost irradiation). The primary outcome was ipsilateral breast tumor recurrence. Important secondary outcomes were skin toxicities using Radiation Therapy Oncology Group scores, Late Effects Normal Tissue Task Force and Subjective, Objective, Management, Analytic scales, and adverse cosmetic outcome. This interim analysis focuses on the secondary endpoints of radiation toxicities and cosmesis. Patient and tumor characteristics and rates of adverse cosmetic outcomes and skin toxicities were compared using Fisher exact tests. All statistical tests were 2 sided, with < .05 considered statistically significant.
Between June 2011 and December 2015, 133 women with breast cancer were randomized to 3D-CRT APBI or WBI. Patient and tumor characteristics were balanced between the 2 arms. Median follow-up was 60 months (range, 12-93 months). Grade 4 late toxicity was not seen in either of the treatment arms, and grade 3 toxicity was very low for each endpoint assessed in both the groups. The rates of grade ≥2 acute dermatitis were 8% and 15%, respectively, for APBI and WBI ( = .18). Rates of grade ≥1 late radiation toxicities were higher in the WBI arm compared with the APBI arm for breast shrinkage ( = .008), pigmentation ( = .028), fibrosis ( = .040), induration ( = .048), and edema ( = .33). Adverse cosmesis at last follow-up was significantly higher in patients treated with WBI: 33% compared with 6% with APBI ( < .001).
In women with breast cancer after BCS, APBI was associated with better cosmetic outcome and fewer late radiation toxicities than WBI.
比较保乳手术后接受三维适形外照射放疗的乳腺癌患者,接受加速部分乳腺照射(APBI)或全乳照射(WBI)后的急性和晚期皮肤毒性发生率以及美容效果。
年龄大于35岁、接受保乳手术治疗的浸润性或非浸润性乳腺癌且肿瘤最大径≤4 cm的女性患者,被随机分为三维适形放疗APBI组(34 Gy/10次/5天)或WBI组(40 Gy/16次/3周±瘤床加量照射)。主要研究终点为同侧乳腺肿瘤复发。重要的次要研究终点为采用放射肿瘤学组评分、正常组织晚期效应特别工作组评分以及主观、客观、管理、分析量表评估的皮肤毒性,以及不良美容效果。本次中期分析聚焦于放射毒性和美容效果这些次要终点。采用Fisher精确检验比较患者和肿瘤特征、不良美容效果发生率以及皮肤毒性发生率。所有统计检验均为双侧检验,P <.05认为具有统计学意义。
2011年6月至2015年12月期间,133例乳腺癌女性患者被随机分为三维适形放疗APBI组或WBI组。两组患者和肿瘤特征均衡。中位随访时间为60个月(范围12 - 93个月)。两个治疗组均未观察到4级晚期毒性反应,两组中各评估终点的3级毒性反应发生率均很低。APBI组和WBI组≥2级急性皮炎发生率分别为8%和15%(P = 0.18)。在乳腺萎缩(P = 0.008)、色素沉着(P = 0.028)、纤维化(P = 0.040)、硬结(P = 0.048)和水肿(P = 0.33)方面,WBI组≥1级晚期放射毒性反应发生率高于APBI组。末次随访时WBI组患者不良美容效果显著高于APBI组:分别为33%和6%(P < 0.001)。
在保乳手术后的乳腺癌女性患者中,与WBI相比,APBI的美容效果更好,晚期放射毒性反应更少。